Jul 1, 2026 07:00AM
Jul 1, 2026 07:00AM
Jun 1, 2026 04:30PM
May 27, 2026 07:00AM
May 6, 2026 07:15AM
Apr 29, 2026 07:01AM
Apr 29, 2026 07:00AM X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union
Apr 1, 2026 04:30PM
Mar 17, 2026 07:15AM
Mar 9, 2026 06:40AM
Mar 4, 2026 07:00AM
Mar 2, 2026 04:30PM
Feb 27, 2026 07:03AM
Feb 27, 2026 07:00AM X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
Sep 29, 2025 07:30AM
Sep 29, 2025 07:30AM
Sep 8, 2025 07:00AM
Sep 8, 2025 07:00AM
Jun 10, 2025 08:02AM
Jun 10, 2025 08:00AM
Mar 25, 2025 06:01AM X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Feb 19, 2025 07:35AM
Feb 19, 2025 07:35AM
Jan 29, 2025 02:48PM
Jan 24, 2025 07:38AM
Jan 24, 2025 07:36AM
Jan 13, 2025 07:35AM
Jan 13, 2025 07:35AM X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
Aug 8, 2024 06:01AM
May 9, 2024 06:30AM
May 9, 2024 06:30AM
May 7, 2024 06:01AM
Apr 29, 2024 06:30AM
Apr 29, 2024 06:30AM
Mar 21, 2024 06:01AM X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
Dec 12, 2023 06:54AM
Nov 9, 2023 06:01AM
Oct 31, 2023 08:02AM
Oct 31, 2023 08:00AM
Oct 18, 2023 08:02AM
Oct 18, 2023 08:00AM
Sep 5, 2023 08:01AM X4 Pharmaceuticals (XFOR) Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor
Sep 5, 2023 08:00AM
Aug 10, 2023 06:05AM
Aug 8, 2023 04:07PM
Aug 8, 2023 04:05PM
May 16, 2023 04:01PM
May 16, 2023 04:01PM
May 15, 2023 09:10AM Key Biotech Events to Watch, Week of 5/15/2023
May 15, 2023 09:08AM

324,764 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All